ctDNA also offers the possibility to detect acquired resistance mechanisms, including the second T790M mutation of EGFR, amplification of MET or HER2, and mutations of PIK3CA or BRAF, for early stage lung cancer patients under first-generation TKI medication [70]. The gene discussed is BRAF; the disease is lung carcinoma.